For the Inventor, By the Inventor

Enter assignee name

Sundbyberg, Sweden

Biolamina Ab

Calculating rank

USPTO Granted Patents = 22

CIPO Patents = 1

EPO Patents = 10

Trademarks = 6

Forward Citations = 21

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Karl Kristian Tryggvason (14 out of 30 patents)

Sergey Rodin (6 out of 7 patents)

Anna Domogatskaya (5 out of 6 patents)

4. Kristian Tryggvason (5 out of 5 patents)

5. Outi Hovatta (4 out of 4 patents)

6. Karl Tryggvason (4 out of 5 patents)

7. Yan Wen Yap (3 out of 3 patents)

8. Agnete Kirkeby (2 out of 2 patents)

9. Malin Pernilla Parmar (2 out of 2 patents)

10. Sun Yi (2 out of 2 patents)

11. Louise Kristina Hagbard (2 out of 2 patents)

12. Carl Gunnar Jesper Ericsson (2 out of 2 patents)

13. Katherine Rachel Cameron (2 out of 2 patents)

14. David Colin Hay (2 out of 3 patents)

15. Stuart John Forbes (2 out of 2 patents)

22 patents: Sort by Forward Citations

1. 12680078 - Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins LN-511, LN-521 and LN-221 (2026-07-14),

2. 12516287 - Methods for producing retinal pigment epithelium cells (2026-01-06),

3. 12391915 - Maintenance of differentiated cells with laminins (2025-08-19),

4. 12378527 - Differentiation of pluripotent stem cells using laminins LN-511, LN-521 and LN-221 (2025-08-05),

5. 12195757 - Methods of producing RPE cells (2025-01-14),

6. 11767509 - Methods of producing RPE cells (2023-09-26),

7. 11713448 - Methods for producing hepatocytes (2023-08-01),

8. 11236302 - Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases (2022-02-01),

9. 11155781 - Maintenance of differentiated cells with laminins (2021-10-26),

10. 11001807 - Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins LN-511, LN-521 and LN-221 (2021-05-11),

11. 10889801 - Methods of producing RPE cells (2021-01-12),

12. 10829733 - Composition and method for enabling proliferation of pluripotent human stem cells (2020-11-10),

13. 10683486 - Methods for producing hepatocytes (2020-06-16),

14. 10344259 - Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases (2019-07-09),

15. 10240124 - Cell culture substrate comprising a laminin and a cadherin (2019-03-26),

Company Overview

Biolamina AB is a biotechnology company based in Sundbyberg, Sweden, specializing in the development and manufacturing of high-quality extracellular matrix products. These products are designed to support cell culture and tissue engineering applications, facilitating advancements in regenerative medicine and cell therapy. The company focuses on providing innovative solutions that enhance cell growth and functionality, contributing to research and development in the life sciences sector. Biolamina's expertise lies in creating biomaterials that mimic natural environments for cells.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

22 Patents

#2 in Sundbyberg

#299 in Sweden

#28,807 in the World

Sundbyberg, Sweden

Biolamina Ab

Forward Citations = 21

21 inventors:

Karl Kristian Tryggvason (14 out of 30 patents)

Sergey Rodin (6 out of 7 patents)

Anna Domogatskaya (5 out of 6 patents)

4. Kristian Tryggvason (5 out of 5 patents)

5. Outi Hovatta (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biolamina Ab. Retrieved from https://idiyas.com/company/biolamina-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…